Maculaser to raise a €1.2 million funding round led by Innovestor.
Maculaser, a Helsinki, Finland-based developer of novel medical technology for treatment of common retinal diseases, announced closing funding of €1.2 million ($1.5M).
The money was raised from investors led by the Finnish venture capital investor Innovestor Ventures with participation from institutional and private investors including business angel Jaakko Ollila and several medical doctors.
The funding will be used to accelerate product commercialization and move the company to the clinical trial phase.
Maculaser, founded in 2020 by CEO Jani Tirronen, Teemu Turunen and Ossi Kaikkonen, develops medical technology used to prevent blindness by targeting major retinal diseases. The devices use retinal temperature-control technology which enables ophthalmologists to perform optimal non-damaging laser therapy without the risk of retinal damage.